logo

BIO

Bio-Rad Laboratories A·NYSE
--
--(--)
--
--(--)
8.80 / 10
Outperform

Comprehensive analysis: excellent fundamentals (8.8/10). Positive dimensions: Revenue-MV and Net income-Revenue, whereas limitations surface in Cash-UP. Resulting position: very promising.

Fundamental(8.8)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.23
Score2/3
Weight9.43%
1M Return1.75%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-6.39%
1M Return-1.45%
Net cash flow from operating activities / Operating revenue (%)
Value19.43
Score3/3
Weight10.68%
1M Return2.00%
Net income-Revenue
Value-0.15
Score3/3
Weight38.23%
1M Return5.66%
Net profit margin (%)
Value2.11
Score3/3
Weight8.89%
1M Return1.64%
Current assets turnover ratio
Value0.64
Score2/3
Weight2.24%
1M Return0.48%
Cash-UP
Value-0.19
Score0/3
Weight-14.93%
1M Return-3.00%
Asset-MV
Value-0.51
Score2/3
Weight8.71%
1M Return1.96%
Net profit / Total operating revenue (%)
Value2.11
Score3/3
Weight8.89%
1M Return1.64%
Cash-MV
Value-0.42
Score3/3
Weight34.23%
1M Return5.04%
Is BIO fundamentally strong?
  • BIO scores 8.80/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.60% ROE, -26.43% net margin, -12.03 P/E ratio, 1.21 P/B ratio, and 14.49% earnings growth, these metrics solidify its Outperform investment rating.